RxDoctor Payments Data

Gerardo Capo, MD

Internal Medicine · Elizabeth, NJNPI 1225049505

Payments from drug & device makers

$23,286in general payments, 2019–2025

Across 483 payments — averaging $48.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Puma Biotechnology, Inc.$7K
  • Gilead$4K
  • Regeneron Healthcare Solutions, Inc.$3K
  • Exelixis Inc.$1K
  • Bayer$771
  • E.r. Squibb & Sons, L.L.C.$669
  • plus $6K from 44 others

What the payments were for

  • Consulting fees$6,50641%
  • Food & beverage$9,26358%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,286 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,115
Medicare patients
182
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib25$406,676
KisqaliRibociclib Succinate18$317,707
PomalystPomalidomide11$253,952
JakafiRuxolitinib Phosphate20$197,319
VenclextaVenetoclax12$186,481
EliquisApixaban41$26,987
OxycontinOxycodone Hcl12$16,557
Ondansetron Hcl112$3,925
Letrozole166$2,620
Oxycodone Hcl77$1,054
Hydroxyurea38$1,030
Anastrozole57$469
Prochlorperazine Maleate37$463
Duloxetine Hcl12$406
Dexamethasone31$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$207$317,70718 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$669$253,95211 claims
Incyte CorporationJakafi$155$197,31920 claims
AbbVieVenclexta$117$186,48112 claims
PfizerEliquis$357$26,98741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Elizabeth

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →